Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 10/20 | 0.52 |
| ▸ | BCR | P11274 | 10/20 | 0.52 |
| ▸ | KDR | P35968 | 6/20 | 0.51 |
| ▸ | FLT1 | P17948 | 5/20 | 0.50 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.45 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18696347 | 0.90 | ABL1 (0.52) | ABL1BCRKDRTTBK1TTBK2 | |
| SCHEMBL18696284 | 0.88 | ABL1 (0.56) | ABL1BCRKDRTTBK1TTBK2 | |
| SCHEMBL18696327 | 0.83 | ABL1 (0.44) | ABL1BCRTTBK1TTBK2 | |
| SCHEMBL18696264 | 0.83 | TTBK1 (0.49) | ABL1BCRTTBK1TTBK2 | |
| SCHEMBL18696189 | 0.83 | ABL1 (0.51) | ABL1BCRTTBK1TTBK2 | |
| SCHEMBL18696239 | 0.83 | ABL1 (0.42) | ABL1BCRTTBK1TTBK2 | |
| SCHEMBL18696353 | 0.83 | AURKA (0.44) | ABL1BCRTTBK1TTBK2 | |
| SCHEMBL18696266 | 0.83 | ABL1 (0.43) | ABL1BCRTTBK1TTBK2 | |
| SCHEMBL18696318 | 0.81 | TTBK1 (0.50) | ABL1BCRTTBK1TTBK2 | |
| SCHEMBL18696319 | 0.81 | ABL1 (0.50) | ABL1BCRTTBK1TTBK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3912973-A2 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3536687-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | Dana Farber Cancer Institute, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-3150593-B1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3150593-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | Dana Farber Cancer Institute, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |